comparemela.com

Latest Breaking News On - Lars fruergaard jorgensen - Page 7 : comparemela.com

Novo Nordisk's results are stunning - and it could be on the brink of something even more exciting

The Danish firm - controlled by the world s biggest charitable foundation - became Europe s biggest company by stock market value last year and claims to have a 85.4% share of the global obesity care market.

China
United-kingdom
Germany
United-states
Canada
Denmark
Switzerland
Americans
Danish
American
German
British

Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy

Sales of Novo’s popular weight loss drug Wegovy more than doubled from this time last year, the company said.

Denmark
Danish
Lars-fruergaard-jorgensen
Eli-lilly
Novo-nordisk
Forbes-breaking-news-text-alerts
Wegovy
Ozempic
Semaglutide

Weight-loss drug maker Novo Nordisk's profits soar further

Weight-loss drug maker Novo Nordisk's profits soar further
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United-states
Denmark
Danish
America
Lars-fruergaard-jorgensen
Fruergaard-jorgensen
Bloomberg
Novo-nordisk
World-obesity-federation
North-america

Novo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drug

Novo Nordisk reported better-than-expected first-quarter profits on Thursday as it looks to fend off competition from rival Eli Lilly

United-states
Denmark
Canada
Poland
Spain
Germany
United-kingdom
Britain
Danish
Eli-lilly
Karsten-munk-knudsen
Markus-manns

Novo Nordisk weight loss drug sales rise as demand for obesity treatments soars

It announced net sales of 65.3billion Danish krone (£7.5billion) for the first quarter of 2023, nearly a quarter higher than the same period last year

United-states
United-kingdom
Denmark
Danish
American
Lars-fruergaard-jorgensen
Novo-nordisk
North-american
Fruergaard-jorgensen
Money

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.